Kuros Biosurgery in Zürich (Switzerland), the bone remodelling biotech for trauma patients, today officially acquired Cytos Biotechnology in Schlieren, the two of which are now to be rebranded ‘Kuros Biosciences’ in a Swiss Stock Exchange merger.
Kuros is developing innovative products for tissue repair and regeneration. The company is a spin-off of the Swiss Federal Institute of Technology (ETH Zurich) and is focused in the areas of medical sealants and bone healing (orthobiologics).
This comes after a €18M (CHF20M) financing of Kuros in November, allowing the Zurich biotech to expand its financial horizons and grow, with sights set on the SIX Swiss Exchange and Cytos.
So what does Cytos bring to the new Kuros Brand?
Well, its infectious disease platforms for viruses such as Hepatitis B are certainly a major draw, several faculties of which are already tied up in partnerships and therefore earning Cytos (now Kuros) a steady income.
One example is Cytos’ clinically validated its virus-like particle (VLP) platform,